Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.

Abdul-Ghani M, Migahid O, Megahed A, Singh R, Kamal D, DeFronzo RA, Jayyousi A

Diabetes, obesity & metabolism15 Jan 2018Cited by 7 (Europe PMC)

PMID29227578DOI10.1111/dom.13189PepBankPUB-29227578

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In poorly controlled T2DM, OGTT C-peptide was the strongest predictor of glycaemic response to pioglitazone plus exenatide.
In plain wordsIn poorly controlled diabetes, insulin secretion best predicted blood sugar response to pioglitazone plus exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableInsulin secretion predicts glycaemic response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin secretion measured with plasma C-peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c ≤ 7.0%) with pioglitazone plus exenatide.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea.
Summary · context
Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2922757801
02HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In poorly controlled T2DM, a 54% C-peptide increment identified glycaemic responders to pioglitazone plus exenatide with 82% sensitivity.
In plain wordsIn poorly controlled diabetes, a C-peptide increase identified responders to pioglitazone plus exenatide with 82% sensitivity.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableGlycaemic response prediction sensitivity
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Sensitivity
82%
54% C-peptide increment
Source sentences
Summary
A 54% increase in 2-hour plasma C-peptide concentration above the fasting level identified subjects who achieved the glycaemic goal (HbA1c < 7.0%) with 82% sensitivity and 79% specificity.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea.
Summary · context
Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2922757802
03HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In poorly controlled T2DM, a 54% C-peptide increment identified glycaemic responders to pioglitazone plus exenatide with 79% specificity.
In plain wordsIn poorly controlled diabetes, a C-peptide increase identified responders to pioglitazone plus exenatide with 79% specificity.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableGlycaemic response prediction specificity
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Specificity
79%
54% C-peptide increment
Source sentences
Summary
A 54% increase in 2-hour plasma C-peptide concentration above the fasting level identified subjects who achieved the glycaemic goal (HbA1c < 7.0%) with 82% sensitivity and 79% specificity.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea.
Summary · context
Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2922757803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.